Trial Profile

An Open-Label Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-JNJ-73841937 (Lazertinib) After a Single Oral Dose in Healthy Male Participants

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 08 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lazertinib (Primary)
Indications Non-small cell lung cancer
Focus Pharmacokinetics
Acronyms hAME study
Sponsors Janssen Research & Development

Most Recent Events

27 Sep 2022 Results assessing Absorption, Metabolism & Excretion Pathways of Lazertinib in Humans presented at the 2022 American College of Clinical Pharmacology Annual Meeting
25 Mar 2021 Status changed from active, no longer recruiting to completed.
25 Feb 2021 Planned End Date changed from 29 May 2021 to 12 May 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com